Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Okabe, Seiichi ^a   Tauchi, Tetsuzo ^a   Katagiri, Seiichiro ^a   Tanaka, Yuko ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic myeloid leukemia; Cytokine; Feeder cell; Imatinib; JAK2 inhibitor

Indexed keywords

BCR ABL PROTEIN; CRK LIKE PROTEIN; FEDRATINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CONTACT; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; FEEDER CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LEUKEMIA CELL LINE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STROMA CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BENZAMIDES; CELL LINE; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOKINES; DRUG SYNERGISM; FEEDER CELLS; FEMALE; HUMANS; IMMUNOBLOTTING; JANUS KINASE 2; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; PYRROLIDINES; RNA INTERFERENCE; STAT5 TRANSCRIPTION FACTOR; SULFONAMIDES;

EID: 84900491177     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-37     Document Type: Article

References (31)

1. Molecular mechanisms of transformation by the BCR-ABL oncogene. Sattler M, Griffin JD, Semin Hematol 2003 40 suppl 1 4 10
2. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J, Ann Intern Med 2006 145 913 923 10.7326/0003-4819-145-12-200612190-00008 17179059 (Pubitemid 351639967)
3. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Helgason GV, Karvela M, Holyoake TL, Blood 2011 118 2035 2043 10.1182/blood-2011-01-330621 21693757
4. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. Sawyers CL, McLaughlin J, Witte ON, J Exp Med 1995 181 307 313 10.1084/jem.181.1.307 7807010
5. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B, EMBO J 1997 16 6151 6161 10.1093/emboj/16.20.6151 9321394 (Pubitemid 27458335)
6. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. Chai SK, Nichols GL, Rothman P, J Immunol 1997 159 4720 4728 9366395 (Pubitemid 127471006)
7. STI-571: an anticancer protein-tyrosine kinase inhibitor. Roskoski R Jr, Biochem Biophys Res Commun 2003 309 709 717 10.1016/j.bbrc.2003.08.055 13679030 (Pubitemid 37122587)
8. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, et al. N Engl J Med 2006 355 2408 2417 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
9. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chroniques, Lancet Oncol 2010 11 1029 1035 10.1016/S1470-2045(10)70233-3 20965785
10. Insights into the stem cells of chronic myeloid leukemia. Sloma I, Jiang X, Eaves AC, Eaves CJ, Leukemia 2010 24 1823 1833 10.1038/leu.2010.159 20861912
11. The JAK-STAT signaling pathway: input and output integration. Murray PJ, J Immunol 2007 178 2623 2629 10.4049/jimmunol.178.5.2623 17312100 (Pubitemid 46333135)
12. Changes in signal transduction downstream from the granulocyte-macrophage colony-stimulating factor receptor during differentiation of primary hemopoietic cells. Wheadon H, Roberts PJ, Watts MJ, Linch DC, Exp Hematol 1999 27 1077 1086 10.1016/S0301-472X(99)00041-7 10378897 (Pubitemid 29275396)
13. Interleukin 3 activates not only JAK2 and STAT5, but also Tyk2, STAT1, and STAT3. Nagata Y, Todokoro K, Biochem Biophys Res Commun 1996 221 785 789 10.1006/bbrc.1996.0674 8630039 (Pubitemid 26153941)
14. BCR-ABL signaling: A new STATus in CML. Fabbro D, Nat Chem Biol 2012 8 228 229 10.1038/nchembio.900 22337094
15. JAK/STAT signaling in hematological malignancies. Vainchenker W, Constantinescu SN, Oncogene 2013 32 2601 2613 10.1038/onc.2012.347 22869151
16. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A, J Clin Oncol 2011 29 789 796 10.1200/JCO.2010.32.8021 21220608
17. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Warsch W, Walz C, Sexl V, Blood 2013 122 2167 2175 10.1182/blood-2013-02-485573 23926299
18. Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation. Xu W, Chen B, Tong X, Int J Hematol 2014 99 87 90 10.1007/s12185-013-1480-z 24293258
19. Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate. Lee YJ, Moon JH, Shin HC, Seo JW, Han SA, Seo SK, Sohn SK, Int J Hematol 2013 97 804 807 10.1007/s12185-013-1326-8 23613267
20. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment. Park SH, Chi HS, Cho YU, Jang S, Park CJ, Kim DY, Lee JH, Lee KH, Ann Lab Med 2013 33 229 232 10.3343/alm.2013.33.3.229 23667855
21. Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML). Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB, Genes Cancer 2010 1 346 359 10.1177/1947601910372232 20798787
22. Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2. Cogle CR, J Natl Cancer Inst 2013 105 378 379 10.1093/jnci/djt029 23446756
23. Role of mitogen-activated protein kinase family in serum-induced leukemia inhibitory factor and interleukin-6 secretion by bone marrow stromal cells. Nakao T, Kim S, Ohta K, Kawano H, Hino M, Miura K, Tatsumi N, Iwao H, Br J Pharmacol 2002 136 975 984 10.1038/sj.bjp.0704797 12145097
24. Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Ernst T, Hochhaus A, Semin Oncol 2012 39 58 66 10.1053/j.seminoncol.2011.11.002 22289492
25. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V, Blood 2011 117 3409 3420 10.1182/blood-2009-10-248211 21220747
26. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ, J Clin Invest 2011 121 396 409 10.1172/JCI35721 21157039
27. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL + progenitors via JAK-2/STAT-5 pathway activation. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A, Blood 2007 109 2147 2155 10.1182/blood-2006-08-040022 17090651 (Pubitemid 46348217)
28. Ex vivo expansion of stem cells: defining optimum conditions using various cytokines. Mohamed AA, Ibrahim AM, El-Masry MW, Mansour IM, Khroshied MA, Gouda HM, Riad RM, Lab Hematol 2006 12 86 93 10.1532/LH96.05033 16751136 (Pubitemid 44044127)
29. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, Leukemia 2008 22 708 722 10.1038/leu.2008.27 18337766 (Pubitemid 351565619)
30. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Okabe S, Tauchi T, Tanaka Y, Katagiri S, Ohyashiki K, Stem Cells Dev 2012 21 2939 2948 10.1089/scd.2012.0016 22642671
31. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells. Okabe S, Tauchi T, Tanaka Y, Ohyashiki K, Biochem Biophys Res Commun 2013 435 506 511 10.1016/j.bbrc.2013.05.022 23684619